Home Contact Us
   
 
 
 
TauRx Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery of Tau Protein Aggregation Inhibitors and other novel therapies and diagnostics for the treatment of Alzheimer's disease (AD) and other neurodegenerative disorders.
We are developing drugs to treat the underlying pathology of AD, to modify or halt disease progression or to prevent it entirely.
TauRx Pharmaceuticals is headquartered in Singapore with primary research facilities in Aberdeen Scotland. TauRx Therapeutics Ltd., WisTa Laboratories Ltd. and Poredeen Pte. Ltd. are wholly owned members of the TauRx Pharmaceuticals Group Company.
 
 
April 2011: TauRx EGM.....  More
January 2011: TauRx AGM.....  More
December 2010: TauRx Press Release...  More
December 2010: TauRx Granted European Composition of Matter Patent for Lead Compound in Treatment and Prevention of Neurodegenerative Diseases including Alzheimer's Disease... More
July 2010: TauRx’s recent Rights Issue over-subscribed ... More
July 2010: New publication from TauRx reviews the role of Tau Aggregation Inhibitor Therapy in Alzheimer's Disease... More
June 2010: TauRx Rights Issue closure extends to 2 July 2010... More
June 2010: TauRx to Present at Jefferies 2010 Global Life Sciences Conference... More
May 2010: TauRx enters collaborative R&D agreement with Bayer Schering Pharma...More
 
 
This website's content is Copyright © TauRx Therapeutics
This website is best viewed in IE6 and above.
Website Designed By Elves Lab
You are Visitor: 127416.